Hemogenyx Pharmaceuticals Plc (HOPHF)
OTC PINK OTC PINK Primary 
Hemogenyx gains as first adult dose cohort is completed
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) has completed the first adult dose cohort in its ongoing Phase I clinical trial for HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia. "Completing the first adult dose cohort is a major achievement in our Phase I trial of HG-CT-1," said Hemogenyx chief executive Dr. Vladislav Sandler.
Hemogenyx Pharmaceuticals secures £709k of new investment
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) has secured £709,200 in fresh investment from an institutional backer keen to support its ongoing clinical trials. The funding, at £1.80 per share, will help advance the company's experimental cancer treatment, HG-CT-1, which is being tested on patients with a hard-to-treat form of leukaemia called relapsed/refractory acute myeloid leukaemia.
Hemogenyx takes major step with AML treatment - ICYMI
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr. Vladislav Sandler talked with Proactive about the company's recent milestone—the first human dose of its proprietary CAR-T cell therapy, HG-CT-1, for treating relapsed refractory acute myeloid leukemia (AML) in adults.
Hemogenyx begins first-human-trial for potentially ground-breaking leukaemia treatment
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) has taken a major step forward in its fight against acute myeloid leukaemia, announcing that it has administered the first-ever dose of its experimental CAR-T cell therapy, HG-CT-1, to a human patient. The treatment is aimed at adults with relapsed or treatment-resistant acute myeloid leukaemia, a condition with limited options and a poor prognosis.
Hemogenyx raises £340,000 for leukaemia clinical trials
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF), the UK-based biotechnology firm, has secured £340,000 through a placing of 100,000 new shares at 340p each. The investment round was underwritten by a single institutional investor, who also received 50,000 warrants exercisable at 500p per share, valid for 12 months from March 1.
Hemogenyx Pharmaceuticals begins patient recruitment at first clinical trial site
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) hailed a "major milestone" as it opened the first trial site and began recruiting patients for the clinical study of its lead drug as a potential treatment for recurrent leukaemia. This Phase I trial of HG-CT-1 in relapsed or refractory acute myeloid leukaemia (R/R AML) in adults is designed as a dose-escalation study to evaluate the safety profile of the drug.
Hemogenyx unveils breakthrough in immune cell technology
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF), the clinical-stage biopharmaceutical company, has announced a significant breakthrough in the delivery of Chimeric Bait Receptors (CBR) to immune cells, marking an important step forward in its development pipeline. This unique approach focuses on enhancing the efficacy of the body's innate immune cells, particularly macrophages and monocytes — white blood cells that serve as the first line of defence against infections and remove damaged or diseased cells.
Hemogenyx Pharmaceuticals gets greenlight for clinical trial
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) shares drove higher in Friday morning’s dealing, rising over 10% at one point, after it received Institutional Review Board (IRB) approval to begin a Phase I clinical trial for its lead therapy, HEMO-CAR-T, formally designated HG-CT-1. The trial will target adult patients suffering from relapsed/refractory acute myeloid leukemia (R/R AML). The Phase I trial is structured as a dose-escalation study to evaluate the safety of HG-CT-1. Secondary objectives will assess the therapy’s efficacy using standard response criteria for AML, as well as estimate overall survival (OS), progression-free survival (PFS), and duration of response (DoR). "We are excited to receive IRB approval to proceed with our Phase I clinical trial of HEMO-CAR-T,” chief executive Dr Vladislav Sandler said in a statement. “This trial is a critical step in the development of our CAR-T therapy for AML patients who have exhausted other treatment options. “With this study, we aim to establish the safety profile of HG-CT-1 and gather preliminary efficacy data that could pave the way for future therapeutic development." In London, Hemogenyx shares were up around 5% changing hands at 1.6p, having traded up to 1.8p earlier. Boeing Co (NYSE:BA, ETR:BCO) has landed an order worth US$2.38 billion for aerial refuelers from the US Air Force. A contract to build a further 15 KC-46A Pegasus tankers was unveiled on Thursday, adding to the 89 delivered to the US Air Force since 2019, Boeing said in a statement. “We appreciate our continued partnership with the US Air Force,” KC-46 programme manager Lynn Fox commented, “this is another big milestone for our team”. The tanker made its first full-scale operational deployment in October after receiving approval for missions by the US in 2022. The deal meant some 168 KC-46As were now under order globally, Boeing added. “We look forward to delivering the world’s most advanced multi-mission aerial refuelers for years to come,” Fox said.
Hemogenyx Pharmaceuticals gets greenlight for clinical trial
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) told investors it has received Institutional Review Board (IRB) approval to begin a Phase I clinical trial for its lead therapy, HEMO-CAR-T, formally designated HG-CT-1. The trial will target adult patients suffering from relapsed/refractory acute myeloid leukemia (R/R AML).
Hemogenyx receives £600,000 institutional boost
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF), the biopharmaceutical company developing treatments for blood diseases, has secured £600,000 in funding from an unnamed institutional investor. The new investment will support the upcoming phase I clinical trials of Hemogenyx's Chimeric Antigen Receptor T-cell therapy, known as HEMO-CAR-T or HG-CT-1.
Hemogenyx Pharmaceuticals provides timeline for trial of potentially breakthrough leukaemia treatment
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) has announced the timeline for its upcoming phase I clinical trial of HEMO-CAR-T, a new treatment for adult patients with relapsed or treatment-resistant acute myeloid leukaemia, a severe form of blood cancer. It has finalised all necessary preparations for the study's first site to open, with the required approval expected by mid-November.
Hemogenyx Pharmaceuticals up 9% after it receives further investment from partner Prevail
Shares in Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) rose 9% after it secured a new $350,000 investment from Prevail Partners, an investment fund, as it gears up for important clinical trials. The investment, which comes at a price significantly above the company's current share value, follows a similar injection of funds in September.
